Kyowa Kirin Co., Ltd. delivered solid FY2025 results that demonstrate the resilience and earnings power of its business model. Revenue of Y496.8B and net income of Y67.0B reflect the company's sustained competitive advantages across its core Drug Manufacturers - Specialty & Generic operations. The H
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required